Welcome to our dedicated page for NGM Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on NGM Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative, life-changing medicines. With a strong focus on cardio-metabolic and liver diseases, NGM Bio leverages its cutting-edge drug discovery platform to generate a pipeline of first-in-class biologic drug candidates, targeting a wide range of disease areas, including cancer.
NGM Bio's approach is deeply rooted in understanding the biology of hormones, cell receptors, and associated ligands. By investigating these biological mechanisms, the company assembles a comprehensive understanding of protein structure-function relationships. This approach, combined with expertise in protein and antibody engineering, allows NGM Bio to create potential first-in-class therapeutics with optimized pharmacologic profiles efficiently.
On the financial front, NGM Bio reported significant progress in 2023. The company continues to advance its clinical-stage solid tumor oncology portfolio with promising results. Additionally, NGM Bio's ALPINE 4 trial for aldafermin, targeting patients with compensated cirrhosis due to NASH, achieved its primary endpoint with positive results. This indicates clinical impact in a challenging patient population and positions aldafermin for potential late-stage development partnerships.
NGM Bio has also made strides in developing NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab). This combination has shown encouraging responses in heavily pretreated patients with advanced disease, including MSS CRC, which is typically unresponsive to anti-PD-1/L1 monotherapy.
In January 2024, NGM Bio announced its strategy to further focus its development efforts on rare conditions with significant unmet needs, such as Primary Sclerosing Cholangitis (PSC) and Hyperemesis Gravidarum (HG). This strategic shift aims to maximize near-term impact and value creation while staying aligned with NGM Bio's mission to deliver transformative medicines for patients.
Moreover, NGM Bio has entered into a definitive Agreement and Plan of Merger with Atlas Neon Parent, Inc., under which all outstanding shares of NGM Bio will be acquired at a price of $1.55 per share in cash. This acquisition is expected to close in the second quarter of 2024, resulting in NGM Bio becoming a privately held company.
Overall, NGM Biopharmaceuticals, Inc. is at the forefront of ushering in new therapeutic options for various diseases, driven by a robust research pipeline and strategic collaborations. For more information, visit NGM Bio's website.
NGM Biopharmaceuticals reported encouraging preliminary results from its Phase 1a trial of NGM120, an antibody targeting GFRAL to treat advanced prostate cancer. The study showed good tolerability, with no dose-limiting toxicities. Notably, two out of five patients exhibited disease control, including one partial response at 62 weeks and PSA reductions. NGM is expanding its research with a Phase 1b cohort testing NGM120 in combination with hormone therapies for metastatic castration-resistant prostate cancer. Further details will be presented at the ESMO Annual Congress on September 11, 2022.
NGM Biopharmaceuticals announced that abstracts for NGM120 have been accepted for presentation at two major conferences: ESMO Annual Congress (September 9-13, 2022) and AACR Special Conference on Pancreatic Cancer (September 13-16, 2022). NGM120 is an antagonist antibody targeting GFRAL to inhibit GDF15 signaling, associated with poor prognosis in various cancers. Presentations will include initial results from Phase 1a and 1b trials focusing on advanced prostate and pancreatic cancer patients, respectively.
NGM Biopharmaceuticals has initiated multiple clinical trials, including Phase 1/1b for NGM438 and Phase 1b for NGM707, both in combination with KEYTRUDA for advanced solid tumors. The company reported a net loss of $46.5 million for Q2 2022, an increase from $36.7 million year-over-year. Collaboration revenue from Merck was notably lower at $8.3 million compared to $16.8 million in the same quarter last year, and is expected to remain diminished through March 2024. Cash and equivalents totaled $297.8 million, down from $366.3 million at year-end 2021.
NGM Biopharmaceuticals, Inc. (NGM) has announced a leadership transition as Siobhan Nolan Mangini assumes the additional role of President, while continuing as CFO. This change, effective July 1, 2022, reflects her significant impact since joining in 2020. David J. Woodhouse remains CEO, and William J. Rieflin will move from Executive Chairman to Chairman of the Board. The company aims for long-term growth through its diverse pipeline and operational leadership. Notably, Mangini previously raised over $170 million and facilitated a collaboration with Merck.
NGM Biopharmaceuticals will showcase its monoclonal antibody product candidate, NGM621, aimed at treating geographic atrophy, in the last part of the "Explorer Series" on June 29, 2022. This virtual event will feature insights from the research team and Dr. Charles Wykoff.
NGM621 targets complement C3, crucial for managing immune response. The webcast will be available on NGM Bio's website, with a recording accessible for one year post-event. NGM Bio focuses on transformative therapeutics across cancer, retinal diseases, and metabolic disorders.
NGM Biopharmaceuticals, Inc. (NGM) has announced that CEO David J. Woodhouse, Ph.D., will present a company overview and business update at two upcoming investor conferences. The presentations will take place at the Jefferies Healthcare Conference on June 9, 2022, at 8:30 am ET, and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 12:20 pm ET. Live webcasts and replays will be available on NGM's website following the events. NGM focuses on developing innovative therapeutics across several areas, including cancer and metabolic diseases.
NGM Biopharmaceuticals, Inc. (NGM) will host the third virtual R&D event, part of its "Explorer Series," on May 31, 2022. This session will focus on NGM707, a dual ILT2/ILT4 antagonist antibody aimed at enhancing anti-tumor immunity by reprogramming myeloid cells. Presentations will feature NGM Bio’s R&D team and Dr. Marco Colonna from Washington University. The final session will cover NGM621, targeting complement C3 for geographic atrophy treatment. A live webcast will be available on NGM’s website, with a replay archived for one year.
NGM Biopharmaceuticals has initiated a Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody, targeting advanced solid tumors. This trial evaluates NGM438 as a monotherapy and in combination with Merck's KEYTRUDA. With this addition, all three of NGM Bio’s myeloid checkpoint inhibitors—NGM438, NGM707, and NGM831—are now in clinical development. The trial is set to enroll up to 80 patients across various cancer types, aimed at assessing safety, pharmacokinetics, and preliminary antitumor activity.
NGM Biopharmaceuticals, Inc. (NGM) has initiated a Phase 1/1b clinical trial for NGM831, a novel ILT3 antagonist antibody product candidate, as both a monotherapy and in combination with KEYTRUDA for advanced solid tumors. The company reported a net loss of $32.5 million for Q1 2022, compared to $27.5 million in Q1 2021. Related party revenue fell to $20.9 million from $21.6 million year-over-year. NGM also received Fast Track designation from the FDA for NGM621, aimed at treating geographic atrophy. As of March 31, 2022, the company reported cash reserves of $329.8 million.
NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company, announced that CEO David J. Woodhouse, Ph.D., will present an overview and business update at two upcoming virtual investor conferences. The first is the Raymond James LILRB/ILT Symposium on April 26, 2022, at 1:30 PM ET, followed by the B. Riley Securities' 2022 Virtual Neurology & Ophthalmology Conference on April 28, 2022, at 10:30 AM ET. Live webcasts will be available on NGM’s website, with replays archived for 30 days.
FAQ
What is the market cap of NGM Biopharmaceuticals (NGM)?
What does NGM Biopharmaceuticals focus on?
What is the ALPINE 4 trial?
What recent strategic shift did NGM Bio announce?
What is the significance of the NGM Bio and Atlas Neon Parent, Inc. merger?
How is NGM Bio leveraging AI and machine learning?
What are some key highlights from NGM Bio’s recent financial report?
What are the main therapeutic areas NGM Bio is targeting?
What are some NGM Bio products currently in development?
What is NGM Bio's approach to drug discovery?
How can investors access more information about NGM Bio?
